首页|Alpha5 nicotine acetylcholine receptor subunit promotes intrahepatic cholangiocarcinoma metastasis

Alpha5 nicotine acetylcholine receptor subunit promotes intrahepatic cholangiocarcinoma metastasis

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Neurotransmitter-initiated signaling pathway were reported to play an important role in regulating the malignant phenotype of tumor cells.Cancer cells could exhibit a"neural addiction"property and build up local nerve networks to achieve an enhanced neurotransmitter-initiated signaling through nerve growth factor-mediated axonogenesis.Targeting the dysregulated nervous systems might represent a novel strategy for cancer treatment.However,whether intrahepatic cholangiocarcinoma(ICC)could build its own nerve networks and the role of neurotransmitters in the progression ICC remains largely unknown.Immunofluorescence staining and Enzyme-linked immunosorbent assay suggested that ICC cells and the infiltrated nerves could generate a tumor microenvironment rich in acetylcholine that promotes ICC metastasis by inducing epithelial-mesenchymal transition(EMT).Acetylcholine promoted ICC metastasis through interacting with its receptor,alpha 5 nicotine acetylcholine receptor subunits(CHRNA5).Furthermore,acetylcholine/CHRNA5 axis activated GSK3β/β-catenin signaling pathway partially through the influx of Ca2+-mediated activation of Ca/calmodulin-dependent protein kinases(CAMKⅡ).In addition,acetylcholine signaling activation also expanded nerve infiltration through increasing the expression of Brain-Derived Neurotrophic Factor(BDNF),which formed a feedforward acetylcholine-BDNF axis to promote ICC progression.KN93,a small-molecule inhibitor of CAMKⅡ,significantly inhibited the migration and enhanced the sensitivity to gemcitabine of ICC cells.Above all,Acetylcholine/CHRNA5 axis increased the expression of β-catenin to promote the metastasis and resistance to gemcitabine of ICC via CAMKⅡ/GSK3β signaling,and the CAMKⅡ inhibitor KN93 may be an effective therapeutic strategy for combating ICC metastasis.

Yan Fu、Keyu Shen、Hao Wang、Shun Wang、Xufeng Wang、Le Zhu、Yan Zheng、Tiantian Zou、Hongfei Ci、Qiongzhu Dong、Lun-Xiu Qin

展开 >

Hepatobiliary Surgery,Department of General Surgery,Huashan Hospital & Cancer Metastasis Institute,Fudan University,200040 Shanghai,China

Center of Interventional Radiology and Vascular Surgery,Department of Radiology,Zhongda Hospital,Medical School,Southeast University,87 Dingjiaqiao Road,210009 Nanjing,China

Institutes of Biomedical Sciences,Fudan University,200032 Shanghai,China

Key Laboratory of Whole-period Monitoring and Precise Intervention of Digestive Cancer,Shanghai Municipal Health Commission,Minhang Hospital,Fudan University,Shanghai,China

展开 >

国家重点研发计划国家自然科学基金国家自然科学基金National Research Center for Translational Medicine at Shanghai,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine

2023YFC2413200/2023YFC24132019195920381930074NRCTMSH-2023-03

2024

10.1038/s41392-024-01761-z

信号转导与靶向治疗(英文)

信号转导与靶向治疗(英文)

CSTPCD
ISSN：
年,卷(期)：2024.9(4)
  • 49